Poster (Scientific congresses and symposiums)
Tisotumab vedotin + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer: phase 1b/2 ENGOT-Cx8/GOG-3024/innovaTV 205 study dose-escalation results
Monk, BJ; Van Gorp, T; Lorusso, D et al.
20212021 IGCS Annual Global Meeting; August 30-September 2, 2021; virtual. Plenary 5
 

Files


Full Text
Tisotumab.pdf
Publisher postprint (327.27 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Tisotumab; Bevacizumab; Pembrolizumab
Disciplines :
Oncology
Author, co-author :
Monk, BJ
Van Gorp, T
Lorusso, D
O'Cearbhaill, RE
Westermann, AM
Banerjee, S
Collins, DC
Klat, J
Madsen, K
Baurain, JF
Jackson, A
Boere, IA
Pignata, S
Gort, E
Moroney, J
Soumaoro, I
Mondrup Andreassen, C
Nicacio, LV
GENNIGENS, Christine  ;  Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service d'oncologie médicale
Vergote, I
More authors (10 more) Less
Language :
English
Title :
Tisotumab vedotin + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer: phase 1b/2 ENGOT-Cx8/GOG-3024/innovaTV 205 study dose-escalation results
Publication date :
30 August 2021
Event name :
2021 IGCS Annual Global Meeting; August 30-September 2, 2021; virtual. Plenary 5
Event date :
August 30-September 2,2021
Available on ORBi :
since 30 October 2021

Statistics


Number of views
60 (3 by ULiège)
Number of downloads
1 (1 by ULiège)

Bibliography


Similar publications



Contact ORBi